AR078201A1 - Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos - Google Patents

Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Info

Publication number
AR078201A1
AR078201A1 ARP100103564A ARP100103564A AR078201A1 AR 078201 A1 AR078201 A1 AR 078201A1 AR P100103564 A ARP100103564 A AR P100103564A AR P100103564 A ARP100103564 A AR P100103564A AR 078201 A1 AR078201 A1 AR 078201A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluoro
group
ring
substituted
Prior art date
Application number
ARP100103564A
Other languages
English (en)
Inventor
Andiappan Murugan
Mark Ashton
Martin Lindsjoe
Peter Olof Sjoe
John Meigh
Lena Kristina Bergstrom
Anna Kristoffersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR078201A1 publication Critical patent/AR078201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Procesos e intermediarios para prepararlos, composiciones farmacéuticas que los contienen y su uso en terapia. Los compuestos son inhibidores de la elastasa de neutrofilos humanos. Reivindicacion 1. Un compuesto caracterizado porque tiene la formula (1) donde R1 representa hidrogeno o alquilo C1-4; R7 representa un anillo de fenilo o piridinilo, donde dicho anillo está 4- (para) sustituido con fluoro, cloro o CN; X representa N o CR2, donde R2 representa H o fluoro; R3 representa un grupo fenilo sustituido con uno o dos sustituyentes seleccionados de manera independiente entre fluor, cloro y trifluorometilo; L representa alquileno C2-4; R4, R5 y R6 representan independientemente alquilo C1-6; o R4 y R5 pueden estar unidos de manera que el grupo NR4R5 representa un grupo cíclico amonio de 5 o 6 miembros; y Y representa un anion farmacéuticamente aceptable. Reivindicacion 18: Un compuesto caracterizado porque es de la formula (2) donde R1 representa hidrogeno o alquilo C1-4; R7 representa un anillo de fenilo o piridinilo; donde dicho anillo está 4- (para) sustituido con fluoro, cloro o CN; X representa N o CR2, donde R2 representa H o fluoro; R3 representa un grupo fenilo sustituido con uno o dos sustituyentes seleccionados de manera independiente entre fluor, cloro y trifluorometilo; L representa alquileno C2-4; R4 y R5 representan independientemente alquilo C1-6; o R4 y R5 pueden estar unidos de manera que el grupo NR4R5 representa un grupo cíclico de 5 o 6 miembros; o una sal de éste. Reivindicacion 19: Un compuesto caracterizado porque es de la formula (8), o una sal de éste donde R1' representa alquilo C1-4; X representa N o CR2, donde R2 representa H o fluoro; L representa alquileno C2-4; R4' y R5' representan independientemente alquilo C1-6; o R4' y R5' pueden estar unidos de manera que el grupo NR4'R5' representa un anillo heterocíclico no aromático saturado o parcialmente saturado de 5 o 6 miembros que contiene 1 nitrogeno y opcionalmente 1, 2 o 3 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno; y R9 es halo; o una sal de éste.
ARP100103564A 2009-10-02 2010-09-30 Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos AR078201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24808109P 2009-10-02 2009-10-02

Publications (1)

Publication Number Publication Date
AR078201A1 true AR078201A1 (es) 2011-10-19

Family

ID=42983551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103564A AR078201A1 (es) 2009-10-02 2010-09-30 Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Country Status (14)

Country Link
US (1) US8436024B2 (es)
EP (1) EP2483244A1 (es)
JP (1) JP2013506649A (es)
KR (1) KR20120099639A (es)
CN (1) CN102639505A (es)
AR (1) AR078201A1 (es)
AU (1) AU2010302420B2 (es)
BR (1) BR112012007322A2 (es)
CA (1) CA2773618A1 (es)
MX (1) MX2012003644A (es)
RU (1) RU2012116877A (es)
TW (1) TW201118078A (es)
UY (1) UY32918A (es)
WO (1) WO2011039528A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4059499A1 (en) 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9388137B2 (en) 2011-10-31 2016-07-12 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
EP2872509B1 (en) * 2012-07-12 2016-09-14 Chiesi Farmaceutici S.p.A. Inhibition of enzymes
JP6501264B2 (ja) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
CN105339780A (zh) 2013-03-15 2016-02-17 拜耳医药保健有限公司 蛋白酶在中性粒细胞胞外诱捕网中的底物性质
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
GEP20207130B (en) * 2016-05-31 2020-07-10 Chiesi Farm Spa Imidazolone compounds as human neutrophil elastase inhibitors
KR20200020210A (ko) 2018-08-16 2020-02-26 서울대학교산학협력단 식물 추출물을 함유하는 호중구 엘라스타아제 억제용 조성물
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
EP4125891A1 (en) * 2020-03-27 2023-02-08 Aclaris Therapeutics, Inc. Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
PL4106757T3 (pl) 2020-04-16 2024-01-22 Mereo Biopharma 4 Limited Sposoby z udziałem inhibitora elastazy neutrofilowej, alwelestatu, do leczenia choroby układu oddechowego, w której pośredniczy niedobór alfa-1 antytrypsyny
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) * 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
EP2053041A3 (en) 2000-06-12 2009-07-29 Eisai R&D Management Co., Ltd. 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
WO2002053543A1 (fr) * 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Derive de pyridone ayant une affinite pour le recepteur cannabinoide de type 2
US20040235761A1 (en) * 2001-08-14 2004-11-25 Yousuke Furuta Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2003070277A1 (fr) * 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antiprurigineux
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7230017B2 (en) 2002-08-27 2007-06-12 Bayer Healthcare Ag Dihydropyridinone derivatives
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CA2556463C (en) 2004-02-19 2012-08-14 Bayer Healthcare Ag Dihydropyridinone derivatives
JP4825194B2 (ja) 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
KR20070033420A (ko) * 2004-07-13 2007-03-26 린텍 가부시키가이샤 이형시트 및 그 이형시트를 이용해서 얻은 성형품
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
SI2024367T1 (sl) 2006-05-04 2011-04-29 Pulmagen Therapeutics Inflammation Ltd Tetrahidropirolopirimidinedioni in njihova uporaba kot äśloveĺ ki neutrofil elastazni inhibitorji
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
AR069206A1 (es) * 2007-11-06 2010-01-06 Astrazeneca Ab Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
US8436024B2 (en) 2013-05-07
KR20120099639A (ko) 2012-09-11
AU2010302420B2 (en) 2013-07-04
CN102639505A (zh) 2012-08-15
WO2011039528A1 (en) 2011-04-07
MX2012003644A (es) 2012-04-30
AU2010302420A1 (en) 2012-04-19
US20110082155A1 (en) 2011-04-07
BR112012007322A2 (pt) 2017-06-06
UY32918A (es) 2011-04-29
RU2012116877A (ru) 2013-11-10
JP2013506649A (ja) 2013-02-28
TW201118078A (en) 2011-06-01
CA2773618A1 (en) 2011-04-07
EP2483244A1 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
CO6680699A2 (es) Derivados de amina para el control de plagas
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR067927A1 (es) Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
SE0403171D0 (sv) New compounds
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
AR087487A1 (es) Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak)
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure